Laser Therapies Beyond SLT: July 2026 Protocol Innovations

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/laser-therapies-beyond-slt-july-2026-protocol-innovationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Laser Therapies Beyond SLT: July 2026 Protocol Innovations Selective Laser Trabeculoplasty (SLT) is a well-known laser treatment that lowers eye pressure by targeting the eye’s drainage tissue (trabecular meshwork). Recent studies (July 2026) have explored new laser approaches and tweaks to SLT for glaucoma and ocular hypertension. These include modified SLT methods (like non-contact SLT and pulsed lasers), micropulse laser techniques, and canal-focused procedures (using either lasers or tiny implants). We summarize the latest dosing (energy), retreatment rates, pressure‐drop results, and safety findings, and explain what they mean for patients. Modified SLT Approaches (Direct SLT and Micropulse SLT) Researchers continue to refine SLT itself. For example, a new “direct SLT” system treats the drainage tissue without touching the eye. In a large series of 218 eyes, Goldberg et al. (2026) found that 67.0% of eyes reached their target pressure at 2 months after direct SLT【Goldberg2026】. The average eye pressure fell about 3.4 mmHg (a 15.6% drop) from a baseline of ~19.7 mmHg【Goldberg2026】. Importantly, eyes that had never used pressure drops before did even better: about 78.4% of these “treatment-naïve” eyes hit the pressure goal, versus 63.5% of eyes already on medication【Goldberg2026】. Side effects were mild: over half of eyes had a small subconjunctival bleed (a tiny bruise on the eye surface), and only 1.8% had a brief pressure spike; no serious complications were seen【Goldberg2026】. Another line of work uses a pulsed laser for the same 360° treatment area of SLT. This “micropulse” SLT applies many tiny bursts of laser energy to gently stimulate the drainage meshwork. In a head-to-head trial, Abramowitz et al. (2018) found that one year after treatment, micropulse SLT and standard SLT gave very similar pressure drops. About 30–37% of eyes in each group had a ≥3 mmHg drop or ≥20% reduction in pressure【Abramowitz2018】. The big difference was comfort: patients reported significantly less pain during and after the micropulse laser (P=0.005)【Abramowitz2018】. In short, modified SLT methods – whether non-contact or pulsed – appear as effective as standard SLT in lowering pressure, with the advantage of easier delivery and less discomfort【Goldberg2026】【Abramowitz2018】. New Micropulse Laser Treatments Beyond SLT-style procedures, micropulse lasers have been applied in other ways. One major application is ciliary-body cyclophotocoagulation, where laser energy is delivered through the sclera (the white of the eye) to reduce fluid production. In a recent retrospective study of 118 eyes with various refractory glaucomas, Toptan et al. (2026) reported dramatic pressure reductions from micropulse transscleral laser. After one treatment session, mean intraocular pressure (IOP) fell by about 46–56% across glaucoma types (for example, 46.5% in primary open-angle glaucoma, 50.4% in neovascular glaucoma, up to 56.2% in juvenile glaucoma)【Toptan2026】. Overall, the group-wide drop was 48.8%. Initially 66.9% of eyes succeeded (reached target IOP) after one session, and after allowing repeat treatments about 75.4% met the goal by 12 months【Toptan2026】. In practice, most patients (67%) needed just one session, while 28% required two and 5% three sessions up to one year【Toptan2026】. Notably, this powerful pressure lowering came with very few serious side effects. No eye developed dangerous chronic low pressure (hypotony) or shrunken eye (phthisis), complications seen with older cyclodestructive lasers【Toptan2026】. A few mild issues were reported (temporary eye inflammation in 3 patients, small bleeding in 1), and one patient had a transient pupil dilation【Toptan2026】. In summary, micropulse transscleral therapy can cut IOP roughly in half with a 1–2 session protocol, at the cost of mostly minor and temporary effects. The dosing used in these studies was high-power but pulsed: typically a 2,000 mW (2 W) laser with a 31% duty cycle (short “on” bursts totaling about 160 seconds of delivery around the eye)【Toptan2026】. This delivered about 70–80 joules of energy per session. The key is that micropulsing lets the tissue cool between bursts, minimizing collateral damage. Canal-Based Procedures (Excimer Trabeculostomy and Canaloplasty) Researchers are also targeting the eye’s fluid canal (Schlemm’s canal) with new techniques. Excimer Laser Trabeculostomy (ELT) is one such method: a tiny ultraviolet laser makes microscopic holes through the trabecular meshwork into Schlemm’s canal. In a small pilot study (Kallab et al., 2026), patients undergoing cataract surgery plus ELT showed measurable improvement in aqueous outflow. Dye angiography before and after the procedure found a significant increase in fluid flow (p=0.03) across the treated drainage area【Kallab2026】. This suggests ELT can enhance the natural channels, although large-scale pressure data are still pending. Separately, non-laser canal procedures (sometimes grouped here) are showing large pressure drops. For instance, an OMNI canaloplasty/trabeculotomy – a micro-catheter device that dilates Schlemm’s canal and cuts through trabecular meshwork – was studied in 18 patients (Olander et al., 2026). Baseline mean IOP was 26.1 mmHg. After 12–24 months, IOP had dropped to about 15.5 mmHg (a 9.7–10.6 mmHg reduction)【Olander2026】, and most patients reduced or stopped their drops. In fact, 67% of patients were off glaucoma medications by 24 months【Olander2026】. Adverse events were mostly mild; no eye lost vision or suffered major complications, and only one case of dry eye was thought related to the procedure【Olander2026】. This demonstrates that opening the canal can yield a ~40% pressure reduction, comparable to traditional glaucoma surgery but with a very favorable safety profile. Patient Factors and Choosing a Protocol Eye Color/Pigmentation: SLT and micropulse lasers target pigmented cells in the drainage tissue. Evidence suggests micropulse methods work well even in darkly pigmented eyes: animal data show these pulses trigger enzymes that remodel the trabecular meshwork without excessive heat【Abramowitz2018】. In practice, no major differences in efficacy by eye color have been reported. All these laser options are intended for open-angle glaucoma; they are ineffective in eyes with closed or very narrow angles. Angle Status: All the laser treatments above require at least a partially open drainage angle. If your angle is closed, the first step is typically a laser peripheral iridotomy or a cataract operation to open the angle. The canal-based surgeries are usually done in open-angle eyes too (often at the time of cataract surgery). Prior Therapy: Timing matters. The direct SLT study found bigger pressure drops in eyes that had never used drops before【Goldberg2026】. For example, medication-naïve eyes had a 20.2% IOP reduction after 2 months of DSLT, versus 14.2% in eyes already on drops【Goldberg2026】. This suggests earlier use of laser (before maximal medications) may give a better percentage drop. In general, laser trabeculoplasty (any type) can be repeated if needed. In the micropulse cyclo series, about one-third of eyes needed a second session to reach target (yielding ~75% success by one year)【Toptan2026】. Expected Results: Based on these studies, patients can expect a moderate IOP drop on average. SLT or micropulse trabeculoplasty (360° treatment) typically reduces pressure by 15–25%, helping ~30–67% of eyes reach their goal with one treatment【Goldberg2026】【Abramowitz2018】. Micropulse cyclodestruction often gives ~40–50% drops and usually requires scheduling 1–2 sessions【Toptan2026】. Canal procedures (like OMNI) can cut IOP by ~40% as well【Olander2026】. However, individual response varies widely. If you have high baseline pressure or aggressive glaucoma, a bigger intervention (multiple sessions, cyclo, or combined surgery) may be needed versus a mild case where single-session SLT suffices. Safety Profile: All these lasers are generally safe when used correctly. In the new studies, serious complications were rare. SLT (even direct SLT) mainly causes brief redness or tiny bleeds, and pressure spikes were under 2%【Goldberg2026】. Micropulse lasers spare tissue and caused minimal inflammation – in one report almost no eyes had permanent loss of vision or severe hypotony【Toptan2026】. Canal surgeries like OMNI had a few mild events (dry eye, transient inflammation) but no vision loss【Olander2026】. Overall, these methods are much less invasive than traditional surgery (trabeculectomy) and typically do not carry high risks of blindness or severe complications. Conclusion July 2026 studies show that innovations in glaucoma lasers are yielding more options beyond standard SLT. Modified SLT techniques (non-contact devices or micropulse pulses) match SLT’s pressure lowering with the promise of quicker treatment and less discomfort【Goldberg2026】【Abramowitz2018】. Micropulse cyclophotocoagulation is proving to be a powerful tool for hard-to-control glaucoma, cutting pressure by nearly half in many eyes with minimal side effects【Toptan2026】. And canal-targeted procedures (both laser and micro-surgical) are delivering large IOP drops (~10 mmHgSupport the show